Litigation Details for ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)

ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)

Docket		Date Filed	2007-08-09
Court	District Court, D. New Jersey	Date Terminated	2010-08-25
Cause	35:183 Patent Infringement	Assigned To	Dennis M. Cavanaugh
Jury Demand	Defendant	Referred To	Joseph A. Dickson
Parties	GLENMARK PHARMACEUTICALS INC., USA; SANDOZ INC.
Patents	12,280,024; 8,399,015; 8,445,018; 9,399,025; 9,457,023; 9,616,024
Attorneys	BRIAN JEFFREY ROBINSON; MELISSA E. FLAX
Firms	Pepper Hamilton LLP; Saiber, LLC
Link to Docket	External link to docket

Details for ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)

Date Filed	Document No.	Description	Snippet	Link To Document
2007-08-09				External link to document

Eli Lilly v. Actavis Elizabeth: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: September 6, 2026

Eli Lilly and Company sued Actavis Elizabeth LLC in the U.S. District Court for the District of New Jersey after Actavis filed an abbreviated new drug application seeking approval for a generic version of Strattera, Lilly’s atomoxetine product. The dispute centered on U.S. Patent No. 5,658,590, which covered methods of treating attention-deficit/hyperactivity disorder with atomoxetine.

The case was litigated as an ANDA patent action under the Hatch-Waxman Act. The district court issued a merits decision in 2010, and the Federal Circuit addressed the dispute in 2011. The case is reported as Eli Lilly & Co. v. Actavis Elizabeth LLC, 731 F. Supp. 2d 348 (D.N.J. 2010), aff’d in relevant part, 435 F. App’x 917 (Fed. Cir. 2011).

What drug and patents were involved in Eli Lilly v. Actavis?

The product was Strattera, an oral atomoxetine product approved by the FDA for attention-deficit/hyperactivity disorder.

Item	Details
Brand	Strattera
Active ingredient	Atomoxetine hydrochloride
Sponsor	Eli Lilly and Company
Dosage form	Oral capsules
Therapeutic area	Attention-deficit/hyperactivity disorder
Regulatory pathway	ANDA litigation under Hatch-Waxman
Primary patent	U.S. Patent No. 5,658,590
Patent subject matter	Methods of treating ADHD using atomoxetine
District court	U.S. District Court for the District of New Jersey
Case number	2:07-cv-03770
Appellate court	U.S. Court of Appeals for the Federal Circuit

The asserted patent was a method-of-use patent rather than a patent limited to a particular capsule formulation or manufacturing process. The patent covered treatment of ADHD using atomoxetine, a selective norepinephrine reuptake inhibitor.

The case therefore illustrates a recurring Hatch-Waxman issue: whether a generic applicant’s proposed labeling and intended use infringe a method-of-treatment patent even when the generic product itself is chemically identical to the branded product.

What was the legal basis for the lawsuit?

Actavis submitted an ANDA to the FDA for generic atomoxetine. The ANDA filing included a Paragraph IV certification challenging Lilly’s patent rights. A Paragraph IV certification states that the listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Lilly filed suit within the statutory 45-day period. The filing triggered an automatic 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.

The central claims were:

1. Whether Actavis’s proposed atomoxetine product would infringe the asserted method-of-use claims.
2. Whether the asserted claims were invalid for obviousness.
3. Whether the patent adequately described and enabled the claimed method.
4. Whether the patent’s claim scope extended to the use proposed in Actavis’s ANDA.

The dispute did not primarily concern a new chemical entity patent. It concerned the legal reach and validity of Lilly’s later-issued therapeutic-use patent.

What did the district court decide?

The district court held in Lilly’s favor on the principal infringement and validity issues. The court found that Actavis’s ANDA-related conduct implicated Lilly’s patented method of treating ADHD with atomoxetine and rejected Actavis’s principal invalidity challenges.

The opinion addressed claim construction, infringement, obviousness, written description, and enablement. The court treated the patent as enforceable against the proposed generic use despite Actavis’s position that the asserted claims were invalid or not infringed.

The result prevented Actavis from obtaining FDA approval for the challenged generic product during the enforceable period of Lilly’s patent and applicable regulatory exclusivity.

The opinion is reported at 731 F. Supp. 2d 348. The district court’s reasoning was significant because method-of-use claims can create a narrower but commercially meaningful barrier than composition claims. A generic applicant may be able to market a product for nonprotected uses, but the proposed labeling, physician prescribing patterns, and ANDA certification can determine whether the product creates infringement exposure.

How did the Federal Circuit resolve the appeal?

The Federal Circuit addressed the case in Eli Lilly & Co. v. Actavis Elizabeth LLC, 435 F. App’x 917 (Fed. Cir. 2011).

The appellate decision left the district court’s core outcome intact. The Federal Circuit did not authorize immediate generic entry based on Actavis’s principal challenges to Lilly’s patent position. The appellate ruling confirmed that the patent remained an effective barrier to the proposed ANDA product during the relevant period.

The Federal Circuit’s treatment of the case reinforced several points relevant to pharmaceutical patent strategy:

• Claim construction can determine whether a method-of-use patent reaches a generic applicant’s proposed labeling.
• Obviousness must be evaluated against the asserted claims as a whole, not merely against the known pharmacology of the active ingredient.
• A known compound can still support enforceable method claims where the claimed therapeutic use was not adequately established by the prior art.
• ANDA litigation may turn on the proposed use and labeling rather than on the generic product’s chemical identity alone.

What patents protected Strattera?

The principal patent at issue was U.S. Patent No. 5,658,590.

U.S. Patent No. 5,658,590

The patent covered methods of treating ADHD using atomoxetine. Its commercial importance came from the fact that Strattera was approved specifically for ADHD, the indication covered by the asserted claims.

The patent was not equivalent to a broad composition-of-matter patent. Composition patents generally provide broader protection against manufacture, sale, and use of the active ingredient. A method-of-use patent can be narrower, but it can still block an ANDA when the proposed generic labeling includes the patented indication.

Public Orange Book records identified U.S. Patent No. 5,658,590 in connection with Strattera. The patent’s listed expiration was in the late 2010s, with pediatric exclusivity affecting the effective regulatory protection period. The patent’s exact commercial impact depended on the Orange Book listing, pediatric extension, the ANDA applicant’s certification, and the final terms of any court order or settlement.

What was the Orange Book and FDA exclusivity position?

Strattera’s principal protection came from patent rights combined with FDA regulatory exclusivity.

The relevant protections included:

Protection	Commercial effect
Patent listing	Required ANDA applicants to address the listed patent
Paragraph IV certification	Allowed Lilly to bring an infringement action
30-month stay	Delayed FDA approval while litigation was pending, subject to statutory rules
Pediatric exclusivity	Extended the effective period associated with qualifying FDA exclusivity and listed patents
Method-of-use protection	Focused the dispute on the ADHD indication and proposed labeling

Strattera was approved by the FDA in 2002. The product was not protected by the modern eight-year data-exclusivity period applicable to later reference products under current biologic and small-molecule frameworks. The commercial barrier instead depended heavily on patent listing, pediatric exclusivity, and the outcome of ANDA litigation.

When did generic atomoxetine enter the market?

Generic atomoxetine ultimately entered the U.S. market after the relevant Lilly patent and regulatory barriers expired or ceased to block approval. The first generic launches occurred in the late 2010s, after the principal patent protection associated with Strattera had run its course.

The timing demonstrates the practical value of Lilly’s litigation. Even though the asserted patent was a method-of-use patent, the litigation delayed approval of Actavis’s proposed generic product and protected branded sales during the remaining patent and exclusivity period.

Generic entry later became commercially feasible because:

• The principal patent protection expired.
• Pediatric exclusivity ended.
• FDA approval could proceed without the earlier litigation bar.
• Atomoxetine was a small-molecule product, so biosimilar regulation was not relevant.
• Generic manufacturers could compete through ANDA approvals rather than through the biologics pathway.

Was this a biosimilar case?

No. Strattera was a small-molecule drug, and Actavis pursued an ANDA rather than a biosimilar application under the Public Health Service Act.

The principal regulatory and litigation framework was the Hatch-Waxman Act. Biosimilar concepts such as reference-product exclusivity under the Biologics Price Competition and Innovation Act, interchangeability, and patent dance procedures did not apply.

The case is relevant to broader pharmaceutical patent analysis because it shows the difference between:

• ANDA litigation for small-molecule generics;
• biosimilar litigation for biologic products;
• composition patents;
• formulation patents;
• manufacturing patents; and
• method-of-use patents.

Did the case involve formulation or manufacturing patents?

The reported dispute focused on the method of treating ADHD with atomoxetine. It was not primarily a formulation-patent or manufacturing-process case.

That distinction affected the generic-entry analysis. Actavis’s product could be chemically equivalent to Strattera and still face a litigation injunction based on the proposed therapeutic use. By contrast, a formulation patent would typically focus on excipients, release characteristics, dosage forms, particle size, or stability. A manufacturing patent would focus on synthesis, purification, crystallization, or process controls.

The case therefore provided Lilly with indication-specific protection rather than a complete platform monopoly over every possible atomoxetine product.

How strong was Lilly’s patent estate?

Lilly’s patent position was strong for the challenged ANDA because the asserted patent was upheld against the principal validity and infringement attacks. Its strength was narrower in scope than a composition patent but sufficient to delay generic approval.

Factor	Assessment
Patent type	Method of use
Scope	Narrower than a composition patent
Relevance to Strattera	Directly aligned with the approved ADHD indication
Litigation result	Favorable to Lilly
Generic risk during patent term	High for an ANDA carrying the patented indication
Post-expiration risk	High price and market-share erosion from multiple generics
Biosimilar risk	Not applicable
Manufacturing barrier	Not the principal issue
Formulation barrier	Not the principal issue

The patent’s commercial strength came from alignment with the approved indication. A narrower method claim can be commercially powerful when the protected use is the reference product’s principal or only approved use.

What generic launch risks did Actavis face?

Actavis faced several risks:

1. Infringement liability. If the court found infringement, Actavis could not launch the product without exposure to an injunction or damages.
2. Approval delay. The Hatch-Waxman stay delayed FDA approval while the litigation proceeded.
3. At-risk launch exposure. Launching before final resolution could have exposed Actavis to damages and injunctive relief.
4. Labeling constraints. Removing the patented indication might have reduced infringement risk but also affected the commercial value and regulatory usefulness of the product.
5. Invalidity risk. Actavis had to establish that the patent was invalid under the applicable standards.
6. Market timing risk. A delayed launch could reduce the value of any first-filer advantage and increase the risk of competition from other generic applicants.

The case illustrates why a generic applicant’s preferred commercial launch date depends on more than the nominal patent expiration date. Litigation duration, pediatric exclusivity, court orders, settlement terms, FDA approval timing, and the number of competing ANDAs can materially change expected launch economics.

Were there settlement agreements or licensing deals?

The reported appellate record does not establish a separate licensing transaction or a publicly disclosed settlement as the basis for the litigation outcome. The published decisions instead reflect adjudication of the infringement and validity dispute.

No biosimilar licensing arrangement was involved. The relevant commercial relationship was between the branded sponsor and an ANDA applicant challenging a listed small-molecule patent.

What was the competitive and revenue impact?

Before generic entry, Strattera held a protected position in the nonstimulant ADHD market. Generic entry created the standard small-molecule erosion risk:

• lower average selling prices;
• substitution through pharmacy benefit systems;
• loss of formulary preference;
• reduced branded prescription volume;
• accelerated decline after multiple generic approvals.

The impact was likely less severe than for a product with a single-use chronic market and no therapeutic substitutes, because ADHD treatment includes stimulant products and other nonstimulant options. Even so, atomoxetine’s distinct mechanism and patient-specific use supported a meaningful branded franchise during the protected period.

The case’s business significance was concentrated in the timing of generic entry. Maintaining the patent barrier for the remaining term preserved branded revenue and delayed price competition. Once the barrier ended, the economic value of the patent estate declined rapidly because atomoxetine could be manufactured and approved through the generic pathway.

Key Takeaways

• The case involved Lilly’s Strattera product and generic atomoxetine.
• The principal asserted patent was U.S. Patent No. 5,658,590.
• The patent covered treatment of ADHD with atomoxetine.
• Actavis challenged the patent through a Paragraph IV certification.
• The District of New Jersey ruled for Lilly on the core infringement and validity issues.
• The Federal Circuit addressed the dispute in 2011 and left the principal result intact.
• The case involved a small-molecule ANDA, not a biosimilar application.
• The patent was a method-of-use patent, not primarily a formulation or manufacturing patent.
• Lilly’s estate was narrower than a composition patent but commercially strong because it covered Strattera’s approved indication.
• Generic atomoxetine entered after the relevant patent and regulatory protections expired.

FAQs About Eli Lilly v. Actavis Elizabeth

What was U.S. Patent No. 5,658,590 used to protect?

It protected methods of treating attention-deficit/hyperactivity disorder with atomoxetine, the active ingredient in Strattera.

Was Actavis the first generic applicant for atomoxetine?

The reported case establishes Actavis as an ANDA challenger but does not, by itself, establish that Actavis held the first-filer position or retained 180-day exclusivity.

Did the case concern Cymbalta, Cialis, or Alimta?

No. The dispute concerned Strattera and atomoxetine.

Did the court invalidate Lilly’s ADHD patent?

No. The reported district court and Federal Circuit decisions did not eliminate Lilly’s principal patent barrier against the challenged ANDA.

Could a generic manufacturer sell atomoxetine for a non-ADHD use?

Any such strategy would depend on FDA-approved labeling, induced-infringement principles, applicable patent claims, and the facts surrounding marketing and prescribing. The reported case itself concerned the proposed ANDA use connected to ADHD treatment.

References

1. Eli Lilly & Co. v. Actavis Elizabeth LLC, 731 F. Supp. 2d 348 (D.N.J. 2010).

2. Eli Lilly & Co. v. Actavis Elizabeth LLC, 435 F. App’x 917 (Fed. Cir. 2011).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2002). Strattera approval history and prescribing information.

5. 21 U.S.C. § 355(j).